Quick Read VanEck Pharmaceutical ETF (PPH) surged 26% over the past year driven by weight-loss drug demand. Eli Lilly and ...

VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...

Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms ...

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on ...

“PPH requests appear to have been filed for less than 1% of U.S. applications. Why are applicants foregoing the program? While the program does not require payment of a fee per se, the author proposes ...

Below is Validea's ETF fundamental report for VanEck Pharmaceutical ETF (PPH). The report looks at PPH's exposure to the major investing factors including value, quality, momentum and low volatility.

Beginning in July 2006, the United States Patent and Trademark Office (USPTO) has partnered with several other offices in Patent Prosecution Highway (PPH) programs. As of the end of fiscal year 2016, ...